Blood Test Detects Early Signs of Post-Surgery Bone Formation | HO Research

A simple blood test could offer a significantly earlier diagnosis for heterotopic ossification (HO), a frustratingly common complication following surgery, particularly hip replacements. Currently, detecting HO relies on imaging techniques like X-rays, which often miss the initial stages of bone formation in soft tissues, delaying treatment and potentially limiting its effectiveness. New research from Mass General Brigham, published in Nature Communications, suggests a liquid biopsy approach – analyzing circulating cells in the blood – can identify HO risk as early as six hours post-injury, weeks before traditional methods.

What is Heterotopic Ossification?

Heterotopic ossification, is the formation of bone in places it shouldn’t be. It’s most frequently observed after major trauma, severe burns, or joint replacement surgeries. While the exact causes aren’t fully understood, it’s believed to involve a complex interplay of inflammation, cellular signaling, and genetic predisposition. The abnormal bone growth can cause pain, stiffness, and reduced range of motion, significantly impacting a patient’s quality of life. In some cases, surgical removal is necessary, but even then, restoring full function is often challenging, succeeding in less than 75% of cases, according to research highlighted by BrightSurf.

The Promise of a Blood Test

The study focused on circulating mesenchymal progenitor cells (cMPCs) – cells that have the potential to develop into various types of cells, including bone. Researchers used a microfluidic device, dubbed an “iChip,” to isolate these cMPCs from patients undergoing hip replacement and from a mouse model of traumatic HO. They found that these cells exhibited gene expression patterns associated with HO remarkably early after injury – a full 41 days before HO would be visible on an X-ray.

By analyzing the RNA within these cMPCs, the team developed a predictive model capable of identifying individuals at risk of developing HO with up to 90% sensitivity and 100% specificity in human subjects. Which means the test is highly accurate at both identifying those who will develop HO and ruling out those who won’t. Importantly, the model also tracked changes in HO risk following preventative treatments, correlating with reductions in the volume of abnormal bone formation.

How the Research Was Conducted

The research involved both human subjects undergoing hip replacement surgery and a mouse model designed to mimic traumatic HO. RNA sequencing was a key component, allowing researchers to identify specific gene expression signatures associated with the condition. The data generated was deposited in public repositories – GEO under accession codes GSE267142, GSE267143, GSE267144, and GSE316836, and the Flow Repository under FR-FCM-Z7CJ – promoting transparency and allowing other researchers to validate the findings. Although, it’s crucial to note that while the results are promising, the study represents an early step. Further validation in larger, more diverse populations is needed before this test can be widely implemented in clinical practice.

Why Early Detection Matters

The current standard of care often involves administering preventative treatments – radiation and anti-inflammatory drugs – to all hip replacement patients, regardless of their individual risk. This approach exposes a significant number of individuals to potential side effects, such as impaired wound healing or delayed bone union, unnecessarily. A more targeted approach, guided by an accurate early diagnostic test, could minimize these risks and optimize treatment strategies. The research highlights that preventative treatments are most effective when administered within the first week following surgery, underscoring the importance of timely detection.

Beyond Hip Replacement: Broader Implications

While the initial study focused on hip replacement patients, the researchers believe this approach has broader implications for other conditions where HO is a concern, such as severe burns and traumatic injuries. The ability to detect aberrant mesenchymal cell fate – the process by which cells develop into specific types – could also be valuable in understanding and monitoring other diseases involving abnormal tissue formation. The study suggests the potential for “high-throughput screening of at-risk patients and real-time assessment of therapeutic efficacy,” opening doors for more personalized and effective treatment plans.

What’s Next for HO Diagnostics?

Mass General Brigham has filed a patent application (PCT Application No. PCT/US2024/055005) for the apply of this rare cell isolation technology in HO detection, signaling their intent to further develop and commercialize the test. The next steps will likely involve larger clinical trials to validate the findings in diverse patient populations and refine the predictive model. Regulatory review and approval will be necessary before the test can become a standard part of clinical practice. Researchers are also exploring the potential of using this approach to monitor the effectiveness of different HO treatments and to identify new therapeutic targets. Continued research, as outlined in Medical Xpress, will be crucial to translate these promising findings into tangible benefits for patients.